Literature DB >> 19066593

High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.

Hilda Petrs-Silva1, Astra Dinculescu, Qiuhong Li, Seok-Hong Min, Vince Chiodo, Ji-Jing Pang, Li Zhong, Sergei Zolotukhin, Arun Srivastava, Alfred S Lewin, William W Hauswirth.   

Abstract

Vectors derived from adeno-associated viruses (AAVs) have become important gene delivery tools for the treatment of many inherited ocular diseases in well-characterized animal models. Previous studies have determined that the viral capsid plays an essential role in the cellular tropism and efficiency of transgene expression. Recently, it was shown that phosphorylation of surface-exposed tyrosine residues from AAV2 capsid targets the viral particles for ubiquitination and proteasome- mediated degradation, and mutations of these tyrosine residues lead to highly efficient vector transduction in vitro and in vivo. Because the tyrosine residues are highly conserved in other AAV serotypes, in this study we evaluated the intraocular transduction characteristics of vectors containing point mutations in surface- exposed capsid tyrosine residues in AAV serotypes 2, 8, and 9. Several of these novel AAV mutants were found to display a strong and widespread transgene expression in many retinal cells after subretinal or intravitreal delivery compared with their wild-type counterparts. For the first time, we show efficient transduction of the ganglion cell layer by AAV serotype 8 or 9 mutant vectors, thus providing additional tools besides AAV2 for targeting these cells. These enhanced AAV vectors have a great potential for future therapeutic applications for retinal degenerations and ocular neovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19066593      PMCID: PMC2835095          DOI: 10.1038/mt.2008.269

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

Review 2.  Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.

Authors:  Nicholas Muzyczka; Kenneth H Warrington
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

3.  Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.

Authors:  Seiichiro Mori; Lina Wang; Takamasa Takeuchi; Tadahito Kanda
Journal:  Virology       Date:  2004-12-20       Impact factor: 3.616

4.  Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis.

Authors:  Seok H Min; Laurie L Molday; Mathias W Seeliger; Astra Dinculescu; Adrian M Timmers; Andreas Janssen; Felix Tonagel; Naoyuki Tanimoto; Bernhard H F Weber; Robert S Molday; William W Hauswirth
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

Review 5.  Versatility of AAV vectors for retinal gene transfer.

Authors:  Enrico M Surace; Alberto Auricchio
Journal:  Vision Res       Date:  2007-10-17       Impact factor: 1.886

6.  Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.

Authors:  H Petry; A Brooks; A Orme; P Wang; P Liu; J Xie; P Kretschmer; H S Qian; T W Hermiston; R N Harkins
Journal:  Gene Ther       Date:  2007-10-25       Impact factor: 5.250

7.  Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity.

Authors:  Michael Schmidt; Antonis Voutetakis; Sandra Afione; Changyu Zheng; Danielle Mandikian; John A Chiorini
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

8.  Clades of Adeno-associated viruses are widely disseminated in human tissues.

Authors:  Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.

Authors:  Carmen S Peden; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors.

Authors:  Mariacarmela Allocca; Claudio Mussolino; Maria Garcia-Hoyos; Daniela Sanges; Carolina Iodice; Marco Petrillo; Luk H Vandenberghe; James M Wilson; Valeria Marigo; Enrico M Surace; Alberto Auricchio
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

View more
  204 in total

1.  Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept.

Authors:  Astra Dinculescu; Jackie Estreicher; Juan C Zenteno; Tomas S Aleman; Sharon B Schwartz; Wei Chieh Huang; Alejandro J Roman; Alexander Sumaroka; Qiuhong Li; Wen-Tao Deng; Seok-Hong Min; Vince A Chiodo; Andy Neeley; Xuan Liu; Xinhua Shu; Margarita Matias-Florentino; Beatriz Buentello-Volante; Sanford L Boye; Artur V Cideciyan; William W Hauswirth; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

3.  Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats.

Authors:  Wen-Tao Deng; Astra Dinculescu; Qiuhong Li; Sanford L Boye; Jie Li; Marina S Gorbatyuk; Jijing Pang; Vince A Chiodo; Michael T Matthes; Douglas Yasumura; Li Liu; Fowzan S Alkuraya; Kang Zhang; Douglas Vollrath; Matthew M LaVail; William W Hauswirth
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-06       Impact factor: 4.799

Review 4.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

5.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

Review 6.  AAV-mediated gene therapy in mouse models of recessive retinal degeneration.

Authors:  J-J Pang; L Lei; X Dai; W Shi; X Liu; A Dinculescu; J H McDowell
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

7.  Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection.

Authors:  Thomas J Giove; Miguel Sena-Esteves; William D Eldred
Journal:  Exp Eye Res       Date:  2010-08-17       Impact factor: 3.467

8.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

Review 9.  Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina.

Authors:  Pavitra S Ramachandran; Vivian Lee; Zhangyong Wei; Ji Yun Song; Giulia Casal; Therese Cronin; Keirnan Willett; Rachel Huckfeldt; Jessica I W Morgan; Tomas S Aleman; Albert M Maguire; Jean Bennett
Journal:  Hum Gene Ther       Date:  2016-10-17       Impact factor: 5.695

10.  AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice.

Authors:  Xufeng Dai; Juanjuan Han; Yan Qi; Hua Zhang; Lue Xiang; Jineng Lv; Jie Li; Wen-Tao Deng; Bo Chang; William W Hauswirth; Ji-jing Pang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.